Supermax Corporation Berhad

KLSE:SUPERMX Stock Report

Market Cap: RM 2.2b

Supermax Corporation Berhad Valuation

Is SUPERMX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SUPERMX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SUPERMX (MYR0.85) is trading above our estimate of fair value (MYR0.45)

Significantly Below Fair Value: SUPERMX is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SUPERMX?

Key metric: As SUPERMX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SUPERMX. This is calculated by dividing SUPERMX's market cap by their current revenue.
What is SUPERMX's PS Ratio?
PS Ratio3.3x
SalesRM 646.17m
Market CapRM 2.17b

Price to Sales Ratio vs Peers

How does SUPERMX's PS Ratio compare to its peers?

The above table shows the PS ratio for SUPERMX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.3x
KOSSAN Kossan Rubber Industries Bhd
3.4x15.9%RM 5.7b
TOPGLOV Top Glove Corporation Bhd
3.5x23.1%RM 8.8b
HARTA Hartalega Holdings Berhad
5.3x19.5%RM 11.4b
COMFORT Comfort Gloves Berhad
0.8xn/aRM 243.2m
SUPERMX Supermax Corporation Berhad
3.3x26.0%RM 2.2b

Price-To-Sales vs Peers: SUPERMX is expensive based on its Price-To-Sales Ratio (3.3x) compared to the peer average (3.3x).

Price to Sales Ratio vs Industry

How does SUPERMX's PS Ratio compare vs other companies in the Asian Medical Equipment Industry?

31 CompaniesPrice / SalesEstimated GrowthMarket Cap
SUPERMX 3.3xIndustry Avg. 3.3xNo. of Companies46PS02.85.68.411.214+
31 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SUPERMX is expensive based on its Price-To-Sales Ratio (3.3x) compared to the Asian Medical Equipment industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is SUPERMX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SUPERMX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.3x
Fair PS Ratio1.2x

Price-To-Sales vs Fair Ratio: SUPERMX is expensive based on its Price-To-Sales Ratio (3.3x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SUPERMX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentRM 0.84
RM 0.89
+5.6%
8.5%RM 1.01RM 0.82n/a4
Nov ’25RM 0.82
RM 0.89
+8.2%
8.5%RM 1.01RM 0.82n/a4
Oct ’25RM 0.85
RM 0.93
+8.8%
8.1%RM 1.04RM 0.83n/a4
Sep ’25RM 0.79
RM 0.93
+17.8%
8.1%RM 1.04RM 0.83n/a4
Aug ’25RM 0.89
RM 0.96
+8.3%
8.4%RM 1.05RM 0.83n/a6
Jul ’25RM 0.89
RM 0.96
+8.3%
8.4%RM 1.05RM 0.83n/a6
Jun ’25RM 0.89
RM 0.96
+8.3%
8.4%RM 1.05RM 0.83n/a6
May ’25RM 0.85
RM 0.96
+13.3%
8.4%RM 1.05RM 0.84n/a6
Apr ’25RM 0.82
RM 0.96
+17.5%
8.4%RM 1.05RM 0.84n/a6
Mar ’25RM 0.83
RM 0.96
+16.1%
8.4%RM 1.05RM 0.84n/a6
Feb ’25RM 0.94
RM 0.97
+3.7%
10.2%RM 1.10RM 0.85n/a6
Jan ’25RM 0.94
RM 0.95
+1.6%
9.5%RM 1.10RM 0.85n/a6
Dec ’24RM 0.94
RM 0.97
+3.3%
9.9%RM 1.10RM 0.85n/a5
Nov ’24RM 0.78
RM 0.90
+15.6%
8.1%RM 1.04RM 0.85RM 0.825
Oct ’24RM 0.83
RM 0.90
+8.0%
8.1%RM 1.04RM 0.85RM 0.855
Sep ’24RM 0.77
RM 0.85
+10.2%
12.4%RM 1.04RM 0.70RM 0.796
Aug ’24RM 0.85
RM 0.87
+1.8%
16.4%RM 1.05RM 0.70RM 0.896
Jul ’24RM 0.80
RM 0.85
+6.1%
16.2%RM 1.05RM 0.70RM 0.897
Jun ’24RM 0.94
RM 0.80
-15.1%
28.8%RM 1.05RM 0.31RM 0.898
May ’24RM 0.87
RM 0.68
-21.3%
24.0%RM 0.88RM 0.31RM 0.859
Apr ’24RM 0.93
RM 0.68
-26.0%
24.0%RM 0.88RM 0.31RM 0.829
Mar ’24RM 0.74
RM 0.66
-12.0%
22.8%RM 0.87RM 0.31RM 0.839
Feb ’24RM 0.81
RM 0.64
-20.7%
25.4%RM 0.87RM 0.31RM 0.949
Jan ’24RM 0.87
RM 0.64
-26.2%
25.4%RM 0.87RM 0.31RM 0.949
Dec ’23RM 0.86
RM 0.63
-26.2%
24.2%RM 0.80RM 0.31RM 0.949
Nov ’23RM 0.94
RM 0.66
-29.9%
15.5%RM 0.80RM 0.50RM 0.7810

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

TMC Life Sciences Berhad

RM 923.2m

An investment holding company, provides healthcare services in Malaysia.

TMCLIFE

RM 0.53

7D

-2.8%

1Y

-19.8%